Turning Point Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
Three Yield10 CRISPR Genome-Edited Camelina Lines Were Determined to be Similar to Conventional Camelina Varieties…
XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen…
PRINCETON, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — Teclison, a clinical-stage pharmaceutical company developing novel…
ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — CRISPR…
JERSEY, Channel Islands, Feb. 02, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics…
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage…
ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC Biopharma, Inc. (NASDAQ:…
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a private biopharmaceutical company…
SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate…
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor naïve cohort FLORHAM PARK,…
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled…
Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in…
Projected revenue of $9M for fiscal 2022 through its Canadian and global operations, including the…
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the…